Member Info for DugWalker

My suspicion is Ross has put this reach announcement out in the hope of hiking the share price ahead of another placing with all the implications for shareholder dilution.

PSE is not medically validated yo them satisfaction of NHS devidion makers. It had been 'laboratory validated' on a few hundred samples. It is years away from acceptance as s proven medical test. Today's Reach anmouncement by Ross is intended to suggest OBD is on the verge of something when his predecessor chose not to get involved in the Transform project (having first .told shareholders that OBD's participation was 'critical')

These are hard facts. Don't get csught on the wrong side of a temporary price spike.

The only mention of a blood test on the Prostate Cancef Website is a test being developed at Cambridge Uni.

https://www.prostate-cancer-research.org.uk/our-research/

Furthermore OBD are not participants in the ongoing Transform trial which is the large scale trial assessing the candidate technologies for a screening programme. The emphasis in Transfom is MRI screening possibly accompanied with enhanced blood tests such as the Cambridge test or the Scandanavian "Stokholm 3" test.

I have no doubt the Episwitch test will be 'mentioned' in this new report but it most categorically is not a test currently being prioritised for an NHS screening programme.

It's sad to see OBD once again deliberately putting out information that could lead folks to conclude otherwise.

Yet another test lacking proper validation.

Awaiting full validation of episwitch tests and the establishment of obd revenue streams are causes of chronic fatigue.

Looks to be a correction based on the late rebound last night. A higher bid price. Not many trades do far today. My sense is that the RNS vould be interpreted as either negative or positive dependent on perspective and panic selling was pretty much balanced out by opportunistic buying yesterday.

Personally I do now think resumption at Viura is imminent and so I took some more yesterday as this vould well be the bottom.

What question did you ask AI and what information did you provide? Seems a bit drastic to duggestbthe well can't be brought back on stream. Liner is repaired and recovering a pressure probe is not a big deal.

Could they not have included this information about the pressure logger in the 26 August RNS? Also who is being told of bad news head of RNS announcements? 3 times now these sell offs have happened.

Now we know the reason for yesterday's sell off. This is at least the third time in recent times that s sell off has come immediately before bad news arrives.

Heyco starting to look rathet inept. Almost feels like they are intent on constraining revenues to pxen as long as possible. We can only hope that references to problems "sourcing and implementing " equipment needed to resolve technicsl issues was a reference to the equipment now on site. Hopefully resumption of gas and revenue flows are now "imminent".

205 patients and in 82 cases the oncologists did not use the CIRT test to inform their clinical treatment path. Its not terribly convincing.

High time they stopped faffing around with these small sample size trials and focused on winning contracts. That means much larger scale trials are urgently required.

Expect another cash raise on the horizon and this is the preliminary shot across the bows of retail investors.

Begs more questions than it answers. What additional equipment is required and why is it difficult to source? O&G is s major industry served by a multitude of OEM's so it's difficult to understand why sourcing some equipment should be problematic. As for implementation, again why is installation and commissioning an issue?

Heyco not looking good here.

I'm more than delighted to see the progress being made by the Transform project. The technologies being assessed have great promise of saving thousands of lives. The PSE test, whilst a promising technology, has not been clinically validated and the OBD board has chosen, for reasons unknown not to seek participation in the Transform trial. There is only one person on this thread wishing others dead.

You should be thanking me for the education.

@PI. I hope they do "rise like a phoenix" for you but I don't see anything different in terms of the company's approach to make confident they will.

@Chromo. Nice to see a post from a decent person with sound morals and common decency. Thanks for your sentiments.

Wishing cancer on someone is scummy behaviour and I have reported your post. Hopefully you will be banned.

For your information I was quite heavily invested here during Burrow's tenure and have always been a strong advocate of the science behind the Episwitch technology. I sold the majority of my shareholding following a webinar in which Burrows stated that it was critical that OBD be involved in the Transform trial, whilst simultaneously demonstrating he had very little knowledge of the details of the trial. Prior to that I wrote to Prostate Cancer UK who confirmed they were aware of PSE a d would welcome it's inclusion in the trial. The fact it is not included is co formation that OBD has not acted on somethingnits past CEO said was 'critical'.

I have posted straight facts together with a link and a recommendation that folks email OBD or Prostate Cancer UK for independent confirmation if so desired. I'm motivated to try to ensure folks are informed before investing in a share that has cost a lot of people a lot of money.

You can read an overview of the ongoing National screening trisl here:

https://prostatecanceruk.org/research/transform-trial

Note that initial trials to narrow down the options are to be conducted on a cohort of 12000 men but that this is to be extended to 300 000 men for the most promising tests. This contrasts with the cohort of a couple of hundred used by OBD for laboratory vslidation of PSE. Clinical validation is a much more rigorous and costly process. (Transform.trials have a %42 million budget)

You can email ProstatevCancer UK or OBD for confirmation that OBD 'sre NOT candidates in the Transform trials.

Chose to become our major shareholder. They have extensive operating experience. They also understand permitting processes in manyana territories like Spain and Italy.

My gut feel is that it might make sense to follow their example as I sense they know more about the business generally (and PXEN in particular) that retail investors commenting on a chat thread.

@WibbleWobble.

How are do any your bullet points differentiate the current OBD from the OBD of 1-2 years ago? Prior to his departure Burrows assigned most of his over manned VP team to securing sales in the US. How did that pan out?

Until this test is properly validated by trials at scale, sales. private or contracted, will be like hens teeth.

Timelines in engineering projects are not carved in stone and can be subject to slippage for any number of reasons. The jig positive in today's RNS is that the workover is completed. It is frustrating but by no means disastrous that we need to wait another few weeks to resume production at Viura. Worth noting the 10% interest accruing on ourbinitialminvedtment at Viura means that the longer it takes to get production going again the more interest we are earning.

Selva continues to ensure we are generating roughly £4 mpa profit (subject to TTF pricing). A Mcap of £17 million against a £4 mpa revenues stream that will run for >10 years is stupidly low.

Patience is a virtue. Good buying opportunity at these prices

Is being run by Prostate Cancer UK and the NIHR and the NHS. It has a budget of £42 million and tensnof thousands of men will participate. OBD are not involved.

The emphasis is on MRI screening and the Stockholm 3 blood test which was partially validated against a large cohort (tens of thousands) in Scandanavia. The UK trial aims to increase participation of non Caucasian males to ensure validation of Stockholm 3 is more robust.

In a reply to me Prostate Cancer UK stated that they are aware of the PSE test but thst they do not consider trials of a few hundred patients sufficient to validate the test. Given its unvalidated status those suggesting it will be soon be adopted by the NHS are ramping the share price as there is no evidence to support such claims. The reality suggests other tests are favoured.

Or alternatively the backup diagnostics could be one of the tests being assessed in the o going national screening trial, such as MRI scans or Stockholm3. PSE is not one of the candidates.

There is nothing remotely unusual about an investment company's income being less than transparent. I agree it is inconvenient for shareholders but it is the nature of the business.